These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 16774768)
1. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768 [TBL] [Abstract][Full Text] [Related]
2. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708 [TBL] [Abstract][Full Text] [Related]
3. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283 [TBL] [Abstract][Full Text] [Related]
4. 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease. Lin JJ; Yueh KC; Liu CS; Liu JT; Lin SZ Acta Neurol Taiwan; 2007 Sep; 16(3):150-7. PubMed ID: 17966954 [TBL] [Abstract][Full Text] [Related]
5. Contribution of thermolabile methylenetetrahydrofolate reductase variant to total plasma homocysteine levels in healthy men and women. Inter99 (2). Husemoen LL; Thomsen TF; Fenger M; Jørgensen HL; Jørgensen T Genet Epidemiol; 2003 May; 24(4):322-30. PubMed ID: 12687650 [TBL] [Abstract][Full Text] [Related]
6. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Camicioli RM; Bouchard TP; Somerville MJ Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534 [TBL] [Abstract][Full Text] [Related]
8. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Brattström L Neurology; 2001 Jan; 56(2):281; author reply 281-2. PubMed ID: 11160979 [No Abstract] [Full Text] [Related]
9. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Kuhn W; Hummel T; Woitalla D; Müller T Neurology; 2001 Jan; 56(2):281; author reply 281-2. PubMed ID: 11271164 [No Abstract] [Full Text] [Related]
10. Endothelial function markers in parkinsonian patients with hyperhomocysteinemia. Bostantjopoulou S; Katsarou Z; Frangia T; Hatzizisi O; Papazisis K; Kyriazis G; Kiosseoglou G; Kazis A J Clin Neurosci; 2005 Aug; 12(6):669-72. PubMed ID: 16040247 [TBL] [Abstract][Full Text] [Related]
11. C677T mutation of methylenetetrahydrofolate reductase gene and serum homocysteine levels in Turkish patients with coronary artery disease. Yilmaz H; Isbir S; Agachan B; Ergen A; Farsak B; Isbir T Cell Biochem Funct; 2006; 24(1):87-90. PubMed ID: 15648053 [TBL] [Abstract][Full Text] [Related]
12. Cysteine elevation in levodopa-treated patients with Parkinson's disease. Müller T; Kuhn W Mov Disord; 2009 Apr; 24(6):929-32. PubMed ID: 19243072 [TBL] [Abstract][Full Text] [Related]
13. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Caccamo D; Gorgone G; Currò M; Parisi G; Di Iorio W; Menichetti C; Belcastro V; Parnetti L; Rossi A; Pisani F; Ientile R; Calabresi P Neuromolecular Med; 2007; 9(3):249-54. PubMed ID: 17914182 [TBL] [Abstract][Full Text] [Related]
14. Methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genotypes and haplotypes and plasma homocysteine levels in patients with occlusive artery disease and deep venous thrombosis. Spiroski I; Kedev S; Antov S; Arsov T; Krstevska M; Dzhekova-Stojkova S; Bosilkova G; Kostovska S; Trajkov D; Petlichkovski A; Strezova A; Efinska-Mladenovska O; Spiroski M Acta Biochim Pol; 2008; 55(3):587-94. PubMed ID: 18800176 [TBL] [Abstract][Full Text] [Related]
15. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa]. Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319 [TBL] [Abstract][Full Text] [Related]
16. Study on homocysteine levels and methylenetetrahydrofolate reductase gene variant (C677T) in a population of Buenos Aires City. Fridman O; Porcile R; Vanasco V; Junco MN; Gariglio L; Potenzoni MA; Bañes I; Morales A Clin Exp Hypertens; 2008 Oct; 30(7):574-84. PubMed ID: 18855261 [TBL] [Abstract][Full Text] [Related]
17. Association between decreased vitamin levels and MTHFR, MTR and MTRR gene polymorphisms as determinants for elevated total homocysteine concentrations in pregnant women. Barbosa PR; Stabler SP; Machado AL; Braga RC; Hirata RD; Hirata MH; Sampaio-Neto LF; Allen RH; Guerra-Shinohara EM Eur J Clin Nutr; 2008 Aug; 62(8):1010-21. PubMed ID: 17522601 [TBL] [Abstract][Full Text] [Related]
18. Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. De Bonis ML; Tessitore A; Pellecchia MT; Longo K; Salvatore A; Russo A; Ingrosso D; Zappia V; Barone P; Galletti P; Tedeschi G Neurosci Lett; 2010 Jan; 468(3):287-91. PubMed ID: 19909787 [TBL] [Abstract][Full Text] [Related]
19. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Yasui K; Kowa H; Nakaso K; Takeshima T; Nakashima K Neurology; 2000 Aug; 55(3):437-40. PubMed ID: 10932284 [TBL] [Abstract][Full Text] [Related]
20. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Kerkeni M; Addad F; Chauffert M; Myara A; Gerhardt M; Chevenne D; Trivin F; Farhat MB; Miled A; Maaroufi K Ann Clin Biochem; 2006 May; 43(Pt 3):200-6. PubMed ID: 16704755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]